新型结核病药物研发：以莽草酸途径为靶标。
New tuberculosis drug development: targeting the shikimate pathway.
机构信息
Johns Hopkins University, Department of Molecular Microbiology & Immunology, Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD 21205, USA +1 410 614 2975 ; +1 410 955 0105 ;
出版信息
Expert Opin Drug Discov. 2008 May;3(5):565-77. doi: 10.1517/17460441.3.5.565.
BACKGROUND
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, yet no new drugs have been developed in the last 40 years.
OBJECTIVE
The exceedingly lengthy TB chemotherapy and the increasing emergence of drug resistance complicated by HIV co-infection call for the development of new TB drugs. These problems are further compounded by a poor understanding of the biology of persister bacteria.
METHODS
New molecular tools have offered insights into potential new drug targets, particularly the enzymes of the shikimate pathway, which is the focus of this review.
RESULTS/CONCLUSION: Shikimate pathway enzymes, especially shikimate kinase, may offer attractive targets for new TB drug and vaccine development.
背景
结核病（TB）仍然是全球发病率和死亡率的主要原因，然而在过去的 40 年中没有开发出新的药物。
目的
结核病化疗时间极长，而且由于 HIV 合并感染导致耐药性不断增加，这都需要开发新的结核病药物。由于对持留菌生物学的了解不足，这些问题进一步复杂化。
方法
新的分子工具为潜在的新药物靶点提供了新的见解，特别是莽草酸途径的酶，这是本综述的重点。
结果/结论：莽草酸途径的酶，特别是莽草酸激酶，可能为新的结核病药物和疫苗的开发提供有吸引力的靶点。
Zotero 插件